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Abstract
Bile duct carcinoma or well known as cholangiocarcinoma (CCA) is the second 
most common of primary liver malignancy after hepatocellular carcinoma (HCC). 
Although cholangiocarcinoma is a rare cancer, it has an aggressive feature with very 
poor prognosis. The epidemiological profile of cholangiocarcinoma varies widely 
across the world, which is reflecting the exposure of different risk factors, such as 
chronic inflammatory disease of the biliary tract, specific infectious disease, and 
congenital malformation. Diagnosis of CCA is quite challenging. CCA is generally 
asymptomatic in the early stages. Therefore, the management of this malignancy 
is often delayed due to late diagnosed, where the metastasis has already present or 
even when it is causing bile duct obstruction. Treatment for CCA is often difficult 
and should be managed in the tertiary referral hospital with a multidisciplinary 
team approach. Surgical treatment with complete resection could be benefit only 
for patient with early stage of the disease. Other treatment modalities as adjuvant 
therapy are also have been developed to improve survival of the patient, such as 
chemotherapy, radiotherapy, molecular targeted therapy, targeting angiogenesis 
and EGFR, and immunotherapy. Recently, immunotherapy has also been devel-
oped as a new cancer treatment option and showed a promising result. Whether 
immunotherapy can be useful for treatment biliary malignancy is still controversial. 
Hence, a lot of studies is still required to confirm the preliminary findings.
Keywords: bile duct carcinoma, bile duct carcinoma management, immunotherapy, 
gastroenterology
1. Introduction
The bile duct carcinoma or known as cholangiocarcinoma (CCA) by the definition 
is a malignancy that originate from cholangiocytes lining the biliary tree. It is included 
in liver malignancy and become the second most common primary liver malignancy 
after hepatocellular carcinoma. [1, 2] Incidence of this malignancy is 10–20% cases 
of all hepatic cancer. [2, 3] Although cholangiocarcinoma is a rare cancer, it has an 
aggressive feature with very poor prognosis. The data showed that the incidence of 
cholangiocarcinoma among gastrointestinal cancer approximately reaches 3% but has 
nearly 20% of death from all hepatobiliary cancer. [3, 4] In addition, cholangiocar-
cinoma is a clinically silent disease at early stage. Therefore, the diseases are usually 
diagnosed at advanced stage with poor prognosis.
Immunosuppression
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CCA may occur anywhere in the biliary tract, however, based on where the tumor 
arises in the biliary tree, it is classified into intrahepatic (iCCA) and extrahepatic 
bile duct cholangiocarcinoma (eCCA). Extrahepatic bile duct cholangiocarcinoma 
is divided into two types, perihilar (pCCA) and distal (dCCA) cholangiocarcinoma. 
iCCAs arises above the second - order of the bile ducts. In contrary, the point ana-
tomical which is distinction pCCA and dCCA is the insertion of the cystic duct.  
The majority of cholangiocarcinoma are in the perihilar (50–60% cases) and distal 
region (20–30% cases), and only 10% of CCA are located in intrahepatic. [5]
The tumor is considered rare in most countries with incidence rate from 
2001 to 2015 was 1.26 cases per 100,000 persons and has a mortality rate 1–6 per 
100,000. [1, 6] Nevertheless, this malignancy is still an endemic disease with high 
prevalence and incidence in some countries or regions such as Thailand and South 
Korea. The epidemiological profile of cholangiocarcinoma varies widely across 
the world, which is reflecting the exposure of different risk factor, such as chronic 
inflammatory disease of the biliary tract, specific infectious disease, and congenital 
malformation. In western countries, primary sclerosing cholangitis (PSC) causing 
biliary obliterative fibrosis, is the major etiology of CCA. [7] Specific in endemic 
area, Northeast Thailand, with incidence rate 118.5 per 100.000, which is 100 
times higher than the global rate. [8] Number of mortality cases from liver and bile 
duct cancer is the leading cause of death in Thai males and places the third place in 
female with total number 28.000 deaths per year. [9] Northeast region of Thailand 
showed the highest number of liver mortality, comprising 70% of cases. [9] In this 
area, incidence of CCA is strongly related to liver fluke infestation that is endemic 
in Mekong River. Liver fluke infection is caused by water-borne parasites known as 
Opisthorchis viverrini, Clonorchis sinensis, and Opisthorchis feluneus. These parasites 
are transmitted to human by the consumption of raw, pickled, or undercooked 
infected fish associated with local tradition and poor income. [10–12]
The life cycle of this parasite is quite complex, involving two intermediate host 
(snail to fish) and including several changes of morphological feature. Fish contami-
nated with metacercaria is ingested by the human. [2] Infected human excretes the 
egg produced by the mature adult worms in their feces. [2, 13] Feces then contami-
nated the fresh water and then ingested by snail and the larva develop and hatch in 
the digestive tract of the snail. [2, 13] After that, thousands of cercariae were excreted 
into the water and penetrate the skin fish, encyst, and forming metacercaria. In the 
body of human, this parasite excyst in the duodenum and ascend to the bile duct via 
the ampulla of Vater then migrate further into the smaller and proximal bile duct, then 
become mature worm and able to sexually produce. [2, 13] Adult worm could survive 
up to 25 years in the biliary tree and causing mild symptoms such as malaise, abdomi-
nal discomfort, and diarrhea. Long term complication of this infection associated 
with hepatomegaly, chronic infection, cholecystitis, gallstone, and periportal fibrosis. 
[2, 13] Long term of chronic inflammation found to be a major etiological precursor 
of hepatobiliary malignancy, predominantly of CCA. Once a person is infected and 
suffered from chronic infection and inflammation, the risk for having CCA is increas-
ing and could present within 30–40 years after infection. [11] Until now, the prognosis 
of CCA is remain poor and death tend to occur within 3–6 months after diagnosis. [11] 
There are several hypothesizes on the mechanism or pathway how the chronic infec-
tion could develop become malignancy: 1) mechanical damage caused by the fluke 
sucker, 2) fluke toxic secretary product, and 3) immunopathological host response. 
[11] These pathways then caused proliferative response and formation of precursor 
lesion such as epithelial and adenomatous hyperplasia, and goblet cell metaplasia. [11]
Beside parasite infection, primary sclerosing cholangitis (PSC) is another com-
mon etiology of cholangiocarcinoma, especially in the western population. PSC is a 
progressive cholestatic biliary characterized by the chronic inflammation that leads 
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to destruction of the intra and extrahepatic bile duct. [14] The incidence rate of PSC 
ranges from 0 to 1.3 per 100.000 people. [15] At early stage, PSC is asymptomatic 
and is usually already diagnosed at advanced stage whereas jaundice and pruritus 
are the major complaint due to cholestasis. It has been also strongly associated with 
inflammatory bowel disease (IBD). On the other hand, PSC is often found with por-
tal hypertension, cirrhosis, and in hepatobiliary and colorectal malignancies. [16, 17]
The other risk factor for developing CCA is biliary stones which is formed in 
the biliary tree, substantially in intrahepatic bile duct or known as hepatolithiasis. 
Biliary stones are typically concomitant with biliary stasis, cholangitis, strictures, 
and bacterial infection, leading to long term inflammation and biliary injury, and 
at the end, increasing the risk of malignant cholangiocytes growth. [18] Abnormal 
morphological also increase the risk for malignant transformation. Choledochal 
cysts is a rare congenital malformation characterized by dilatation of the biliary 
tree, can be single or multiple, and can be developed in the intra or extra hepatic 
bile ducts. [17, 19] Moreover, the coincidence of abnormal pancreatobiliary duct 
junctions increases the possibility of cholangiocarcinogenesis. This due to pancre-
atic enzyme reflux, cholestasis, and elevated bile acid concentrations. [19]
Exposure to chemical carcinogens such as Thorotrast, halogenated hydrocarbon 
solvent, and 1,2-dichloropropane were found to be associated with CCA incidence. 
[20, 21] Carcinogens-induced liver insult has been showed to promote hepatocyte 
remodeling, genomic instability, DNA methylation, and disrupt the liver architec-
ture. Moreover, some studies reported few genetic mutations related to hepatobili-
ary malignancy. [22] Hepatic disease associated with CCA include alcoholic liver 
disease, cirrhosis, and cholangitis are included become risk factor. [17]
Diagnosis of CCA is quite challenging. CCA is generally asymptomatic in the 
early stage. Therefore, management of this malignancy is often delayed due to 
late diagnosed, where it already metastasis or compress the bile duct. The clinical 
features of CCA are heterogenous, with general malaise, cachexia, abdominal pain, 
night sweats, fatigue, weight loss, asthenia, and/or jaundice which is more frequent 
symptom in pCCA and dCCA due to biliary tract obstruction. [23, 24] Diagnosis of 
CCA is usually confirmed by combining nonspecific biomarkers in serum, biopsy 
specimens, and imaging technique. To date, there is no specific serum marker 
available for diagnosing CCA. Liver function parameters such as serum bilirubin, 
alkaline phosphatase, and aminotransferase enzyme usually elevate when biliary 
obstruction is presence. [24, 25] However, it is not specific signs for biliary malig-
nancy. Serum tumor marker such as carbohydrate antigen (CA) 19–9, CA-125, and 
carcinoembryonic antigen (CEA) are the most widely used markers for suspected 
CCA. [25] But this diagnostic tool should not be used alone due to their poor 
diagnostic performance and inherent limitations.
Imaging techniques which are required to help diagnosis CCA are trans-
abdominal ultrasonography (US), contrast-enhanced ultrasonography (CEUS), CT 
scan, and MRI. Becoming diagnostic tools, imaging techniques play a key role in 
the management of CCA in term of diagnosis, staging, follow-up, and assessment 
of favorable treatment response. The accuracy of diagnosis is depending on the 
anatomical location and growth pattern of CCA. Magnetic resonance cholangiopan-
creatography (MRCP) has the higher diagnostic accuracy for sizing strictures and 
localizing. [24, 25]
But unfortunately, there are no specific CCA radiology pattern exists. Therefore, 
histopathology or cytological analysis is also necessary for confirming the diagnosis. 
Definitive diagnosis is usually made by undergoing endoscopic retrograde cholangio-
pancreatography (ERCP) procedure for fluid cytology, brush cytology, fluorescence 
in situ hybridization (FISH), and cholangioscope or chromoendoscopy-guided 
biopsy. [26–28] Those multiple diagnostic modalities are required to 1) establish 
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strictures anatomical location; 2) distinguish between benign and malignant 
strictures; 3) differentiate CCA from gallbladder cancer; 4) stage and grade the 
tumor; and 5) plan treatment approach. Based on WHO classification of biliary tract 
cancer it is showing an adenocarcinoma or mucinous carcinoma, with tubular and/or 
papillary structures and a variable fibrous stroma. [24, 25]
Determine staging of CCA is important for choosing the treatment, its resect-
ability, and the outcome of the treatment. TNM classification system of American 
Joint Committee on Cancer (AJCC) and Union for International Cancer Control 
(UICC) has been used at present to determine the staging of CCA. TNM stag-
ing system is based on imaging tests which is evaluating the number of primary 
nodules, vascular invasion, direct extension in neighboring tissue, and bile duct 
involvement. [29] pCCA can be further divided according to the Bismuth-Corlette 
classification, depending on the size of the tumor, disease extension in the main bile 
duct, hepatic artery and/or portal involvement, lymph node involvement, distant 
metastasis, and remnant liver volume after resection. [30] iCCA could be classified 
based on 3 growth pattern which has different prognosis of each pattern: mass-
forming (MF-iCCA), periductal infiltration (PI-iCCA), and intraductal growth 
(IG-iCCA). [31]
Treatment for managing cholangiocarcinoma is quite difficult too and should 
be managed in the tertiary hospital with a multidisciplinary team experienced in 
endoscopic, percutaneous, and surgical approaches. Management of this malig-
nancy also depends on the staging of the tumor. Surgical treatment with complete 
resection could give benefit only for patient with early stage of the disease [32].
Resection could be performed in approximately 30% of patient with CCA. This 
is the only option that provides a real possibility for long-term survival in patient 
diagnosed with CCA. The indication and extension of surgery are determined based 
on clinical features of the patient, functional liver reserve, and the location and 
extension of the tumor, which include the association with vascular structure and 
negative metastatic disease. [33, 34]
Criteria for patients who are considered as absolute unresectability are the 
presence of nonresectable extrahepatic, hepatic metastases, bilateral extension of 
the tumor with involvement of the secondary biliary tract, complete occlusion of 
the main portal vein, thrombosis in portal vein contralateral to the tumor. [23] The 
most common postoperative complications are hemorrhage, infection, liver failure, 
cardiorespiratory failure, and adrenal failure. Mortality and morbidity for postop-
erative patient are still remaining high, 8,2% and 50%, respectively. [35] In several 
condition, drainage should be applied. But in the recent years, increasing number 
of patients with unresectable intrahepatic and extrahepatic CCA are being included 
to be candidate for liver transplant. Other treatment modalities as adjuvant therapy 
are also developed to improve the survival of the patient, such as chemotherapy, 
radiotherapy, molecular targeted therapy, targeting angiogenesis and EGFR, and 
immunotherapy.
2. Role of immunotherapy in cancer management
2.1 History and definition
Cancer immunotherapy is significantly progressing and rapidly advancing. 
In the recent years, immunotherapy is considered to be the fifth pillar of cancer 
therapy and management modality besides surgery, cytotoxic chemotherapy, radia-
tion, and targeted therapy. The mechanism of immunotherapy in cancer manage-
ment is to determine a manipulation of the immune system by using immune 
5
The New Era of Immunotherapy in Bile Duct Cancer Management
DOI: http://dx.doi.org/10.5772/intechopen.94754
agents such as vaccine, cytokine, cell therapies and humoral, transfection agent. 
Cancer immunotherapy has to stimulate the host anti-tumor response by increasing 
the effector cell number and production of soluble mediators, decrease the host’s 
suppressor mechanism by inducing tumor killing environment, and could modulate 
immune checkpoint. [36, 37]
In 1891, William Coley, who is known today as the Father of Immunotherapy, 
injected heat inactivated bacteria or known as Coley toxins to the sarcoma patient 
who was inoperable. [38] This first experiment resulted in long term regression of 
the sarcoma after an erysipelas infection after injecting the toxin. [38] By late 1970s, 
immunotherapy for managing cancer was discovered. The first experiment was 
done in bladder cancer case which is managed by using BCG (Bacillus Calmette-
Guerin). Then, it is continued with IFN therapy in malignant melanoma. [39] Brief 
background review of immune system is classically considered to be comprised of 
the innate and adaptive arms. Immune system which are included in innate immune 
system are dendritic cells, natural killer cells (NK), macrophages, neutrophils, 
eosinophils, basophils, and mast cells. As we known, this group of immune system 
does not need prior stimulation by antigen, and it plays role as first line of defense 
against foreign antigens. In the contrary, adaptive immune system consists of 
B lymphocytes, CD4 helper T lymphocytes, and CD 8 cytotoxic T lymphocytes 
(CTLs). This group of immune system requires formal presentation by antigen 
presenting cells (APCs) for its activation. [40, 41]
Several kinds of malignant cells are able to evade the tumor immunosurveil-
lance system by manipulating their own characteristic as well as the cells in their 
microenvironment to become successful tumors. The concept that the immune 
system is capable for detecting and killing nascent non-self-malignant cells was 
developed. Elimination, equilibrium, and escape are three main phases of immu-
noediting process. [42] The elimination phase is the initial damage process and 
destruction of the tumor cell by innate immune system, then tumor antigens are 
presented to the dendritic cells, followed by presentation to the T cell and then 
create tumor-specific CD4 and CD8 T-cells. Second phase occurs when tumor cells 
survive after the initial destruction but are not able to progress and being main-
tained in an equilibrium state. The last phase is escape phase. [42] In this phase, 
tumor cells are growing rapidly, followed by metastasize of tumor cell due to loss 
control of the immune system and the tumor cells do not presented antigens on 
its surface or even losing their MHC class1 expression. Tumor cell could protect 
their self from T cell by expressing immune checkpoint (IC) molecules on their 
surface. [42]
The ability of this malignant cells to evade immune destruction by modulating 
its own cellular characteristic and creating its own “tumor microenvironment” by 
recruiting apparently normal immune cells to help shield it from attack of immune 
system. In addition, tumor cell can influence the systemic environment by altering 
hematopoiesis and tissue parenchyma of organs at distant sites. Cancer immuno-
therapies play role in manipulating these tumor microenvironments. But the loss of 
MHC class 1 expression manipulating is remaining challenge. [43–45]
First, older, and non-specific immunotherapies are the kind of immune stimulator 
cytokines such as interleukin-2 IL-2) and interferon (IFN). [46] Beside that, synthetic 
analogue of bacterial cell wall called L-MTP could activate monocytes and macro-
phages is one of the immunostimulatory cytokines. Vaccine trials using multiple 
neoantigens specific to and individual patient’s tumor have shown promising results 
in two small early trials with the aim to expose patients to those tumor antigens which 
can provoke an antitumor immune response via the generation of tumor specific 
antibodies and T cells. [46] BCG was the first vaccine used as cancer immunotherapy 
for treating bladder carcinoma. [47]
Immunosuppression
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Oncolytic viruses are the combination of biologic therapy and immunotherapy. 
Viruses which are used for this method has genetically modified to lack virulence 
against normal cell but has a selective feature to invade and lyse cancer cells. 
Viral-induced tumor cell destruction undergoing further attack by an immune 
system. [48]
Adoptive cell therapy (ACT) is one type of immunotherapy which involves 
in the isolation and in-vitro expansion of tumor-specific T-cells, which is given 
through infusion in the cancer patient. ACT using NK cells could be used to treat 
solid tumor metastasis and hematological cancers. [49] Several forms of ACT using 
different techniques are culturing tumor infiltrating lymphocytes directly from the 
tumor, isolating and expanding one particular T-cell or the clone, using T cell which 
have been engineered in vitro so that it could recognize and attack the tumor cells or 
known as chimeric antigen receptor T-cell (CAR T-cell) therapy. ACT has produced 
remarkable result in clinical trials with melanoma and hematologic malignancies. 
But some studies reported death have occurred in the trial phase due to cytokine 
release syndrome or cytokine storm. [50]
Another immunotherapy, Immune checkpoint, work by targeting molecules 
that serve as checks in the regulation of immune responses and block inhibitory 
molecules or activate stimulatory molecules and enhance pre-existing anti-cancer 
immune response. [51]
2.2 The clinical importance of immunotherapy
Cancer immunotherapy works to stimulate the host’s anti-tumor response. The 
mechanism included are increasing the effector cell number and production of 
soluble mediators, decreasing the host’s suppressor mechanism by inducing tumor 
killing environment, and modulating immune checkpoints. The usefulness of can-
cer immunotherapy was introduced in the beginning to manage bladder cancer. The 
overall 5-year survival after transmitting immunotherapy is 77%. [39] Patients with 
moderate and high-grade bladder cancer who received intravesical immunotherapy 
with BCG have shown good result. Immune checkpoint inhibitors showed a promis-
ing clinical research in managing anti-cancer immune responses. Several studies 
using Nivolumab, Ipilimumab, and Pertuzumab are still on progress in metastatic 
bladder cancer. Some cytokines which are messenger molecules, play a role to con-
trol the growth and activity of immune system cells. [52] Treatment using cytokines 
as immunotherapy can enhance the activity of the immune system against tumors. 
The link of IL-2 to the antibody, ALT-801, and cytokines can target IL-2 to cancer 
cells. [53] Oncolytic virus therapy could also be used to treat bladder cancer using 
adenovirus which expresses the immune stimulating cytokine GM-CSF. [54]
Immunotherapy is developed to manage some immunogenic cancer cases besides 
bladder cancer. The using of immunotherapy for managing breast cancer have been 
improved and approved in the recent years. Although the best treatment of breast 
cancer is surgery, but combination therapy followed by chemotherapy, radiation 
therapy, or immunotherapy could increase clinical outcome for patient. A promising 
immunotherapy using immune checkpoint inhibitors that work by targeting mole-
cules that serve as checks in the regulation of immune response and block inhibitory 
molecules or activate stimulatory molecules. [39] The other form of immunotherapy 
which can be used for breast cancer is monoclonal antibodies and adoptive T cell 
transfer. By definition, adoptive T cell transfer is a process of removing T cell from 
the patient, then it would be modified genetically or treated with chemical to 
enhance its activity and re-introduced into the patient. Specifically, in breast cancer, 
T cell genetically is modified to target the carcinoembryonic antigen (CEA). [55]
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Another immunogenic cancer is cervical cancer caused by infection of human 
papillomavirus (HPV). Cervical cancer is the third most frequent cancer among 
women in the world. [56] The prevalence of this cancer is decreasing due to devel-
opment widespread of screening tools Pap test and vaccine to prevent HPV infec-
tion. In the recent years, monoclonal antibodies, checkpoint inhibitor, and adoptive 
T cell transfer have become additional therapy for managing progressivity of cancer 
cell. [39]
Immunotherapies are also developed as a new modality treatment to treat brain 
cancer, colorectal cancer, esophageal cancer, and biliary tract cancer. Probably, in 
time, immunotherapy could lead to personalized medicine that will increase overall 
survival and progression free survival for many treatments. [39]
2.3 The role of immunotherapy in managing bile duct malignancy
Biliary tract malignancy is an invasive carcinoma which can be originated from 
gallbladder or bile duct. It has been known that the immune system in human 
body has a significant role in the surveillance and eradication of cancer cells. 
Tumor that lack the mismatch repair system harbor more mutation than tumor 
without this deficiency. Thus, the neoantigen generated and be recognize as 
immunogenic antigen. The characteristic of mismatch repair deficient tumors is 
microsatellite instability (MSI). There are approximately 3% of CCA are mismatch 
repair-deficient/MSI-high. [56] This feature makes the tumor cells are susceptible 
to programmed cell death protein 1 (PD-1) inhibitors. Zhu et al. studied about 
efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced 
biliary-tract cancers and the correlation of changes in 18-fluorodeoxyglucose PET 
with clinical outcome in a phase 2 study showed that combination of chemother-
apy and immunotherapy have anti-tumor effect with tolerable safety and promis-
ing efficacy for managing advanced biliary tract malignancy. This combination 
treatment was generally well tolerated with less adverse event and manageable 
toxicity. [57]
Another clinical data about immune-directed therapy in CCA is still scanty. 
Vaccine for preventing CCA has been developed and tested but no data has 
showed successful result. [58] CAR T cell immunotherapy in recent years has 
been developed. Guo et al. in their study about expanded and parallel clinical trial 
of EGFR-specific chimeric antigen receptor-engineered autologous T (CART) 
cell immunotherapy. The aim of this study is to assess the safety and activity of 
CART-EGFR cell therapy in EGFR-positive advanced unresectable, relapsed/
metastatic biliary tract cancer. Total sample of this study is 19 patients and showed 
that CART-EGFR cell infusion was tolerated, 1 achieved complete response and 10 
achieved stable disease. We can conclude that CART-EGFR cell immunotherapy was 
a safe and active strategy for EGFR-positive advanced biliary tract cancer. [59] Wei 
et al. showed that in some patients, immune checkpoint blockade using monoclonal 
antibodies has shown remarkable and durable response rate in a many kind of 
malignancy cell. [60] Le et al. in their study concluded that mismatch-repair status 
predicted clinical benefit of immune checkpoint blockade with pembrolizumab 
and achieving objective responses in up to 40% of patients. [61] Study by Ott et al. 
in KEYNOTE-028 basket trial of pembrolizumab included patients with advanced 
biliary tract cancer resulted the objective response rate was 17% with median 
progression-free survival of 1.8 months. [62] However, further studies are required 
either combination immunotherapeutic approaches targeting both the innate 
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3. Conclusions
Bile duct cancer is still one of the challenging malignancies in the gastroenterol-
ogy field due to the difficulty in early detection and most of patients come in the 
late stage of the disease. Chemotherapy is still the main option of management 
despite surgery and biliary drainage. Immunotherapy is a promising treatment 
option in the future; however, further studies would be needed to give strong 
evidence before it can be used in common clinical practice.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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